Free Case Transferred In - District Transfer - District Court of California - California


File Size: 111.5 kB
Pages: 22
Date: July 6, 2007
File Format: PDF
State: California
Category: District Court of California
Author: unknown
Word Count: 6,149 Words, 40,523 Characters
Page Size: Letter (8 1/2" x 11")
URL

https://www.findforms.com/pdf_files/cand/193692/1-14.pdf

Download Case Transferred In - District Transfer - District Court of California ( 111.5 kB)


Preview Case Transferred In - District Transfer - District Court of California
Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 1 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

TUCKER ELLIS & WEST LLP MICHAEL C. ZELLERS-STATE BAR NO. 146904 PETER E. SCHNAITMAN-STATE BAR NO. 218982 SU-LYN COMBS-STATE BAR NO. 209834 TAE-YOON KIM-STATE BAR NO. 209934 1000 Wilshire Boulevard, Suite 1800 Los Angeles, CA 90017-2475 Telephone: 213.430.3400 Facsimile: 213.430.3409 [email protected] [email protected] [email protected] [email protected] Attorneys for Defendants PFIZER INC., PHARMACIA CORPORATION and G.D. SEARLE LLC

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF CALIFORNIA ) ) ) Plaintiffs, ) ) v. ) ) MERCK & COMPANY, INC., a ) corporation; McKESSON ) CORPORATION, a corporation; ) AMERISOURCEBERGEN DRUG ) CORPORATION, a corporation; ) PFIZER, INC.; PHARMACIA ) CORPORATION; G.D. SEARLE LLC, ) (FKA G.D. SEARLE & CO.); DOES 1 ) to 100; PHARMACEUTICAL ) DEFENDANT DOES 101 to 200, and ) DISTRIBUTOR DEFENDANT DOES ) 201 to 300, inclusive, ) ) Defendants. ) ) ________________________________ ) CAROL ANN DAVIES and HARRY DAVIES, Case No. 2:06-CV-02768-MCE-DAD DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT JURY DEMAND ENDORSED HEREIN

DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 2 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

Defendants Pfizer Inc. ( Pfizer ) (erroneously captioned as Pfizer, Inc.), Pharmacia Corporation, G.D. Searle LLC ( Searle ) (erroneously captioned as G.D. Searle LLC, (fka G.D. Searle & Co.)) (collectively Defendants ) for themselves, submit this Answer to Plaintiffs Complaint. 1(a) Causes Of Action and Parties Alleged in the Master Complaint: 1. Paragraph 1 of Plaintiffs Complaint states Plaintiffs own assertions

and legal conclusions to which no response is required. To the extent a response is deemed required, Defendants deny the allegations contained in paragraph 1, including subparts a through b, of Plaintiffs Complaint. 2. Defendants have insufficient information or knowledge concerning

the citizenship of Plaintiffs, and therefore deny the same. 3. Paragraph 3 of Plaintiffs Complaint states Plaintiffs own assertions

and legal conclusions to which no response is required. To the extent a response is deemed required, Defendants deny the allegations contained in paragraph 3 of Plaintiffs Complaint. 4. The allegations relating to Vioxx® are unrelated to Defendants and

therefore no response is required. To the extent a response is deemed required, Defendants have insufficient information or knowledge and therefore deny the same. Defendants are without knowledge with regard to the Plaintiff s prescription and use of Celebrex® and/or Bextra®, and therefore deny the same. Defendants deny the remaining allegations contained in paragraph 4 of Plaintiffs Complaint. 5. The allegations relating to Vioxx® are unrelated to Defendants and

therefore no response is required. To the extent a response is deemed required, Defendants have insufficient information or knowledge and therefore deny the same. Defendants are without knowledge with regard to the Plaintiff s prescription and use of Celebrex® and/or Bextra®, and therefore deny the same. Defendants deny the remaining allegations contained in paragraph 5 of Plaintiffs Complaint.
2.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 3 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

6.

The allegations relating to Vioxx® are unrelated to Defendants and

therefore no response is required. To the extent a response is deemed required, Defendants have insufficient information or knowledge and therefore deny the same. Defendants state that, at times relevant to this lawsuit, Bextra® and Celebrex® were safe and effective when used in accordance with its FDAapproved prescribing information. Defendants state that the potential effects of Bextra® and Celebrex® were adequately described in their FDA-approved prescribing information, which were at all times adequate and comported with applicable standards of care and law. Defendants are without knowledge with regard to Plaintiff s allegations relating to any person s reliance referred to in paragraph 6. Defendants deny the remaining allegations contained in paragraph 6, including subparts a through e, of Plaintiffs Complaint. 7. Defendants deny that Plaintiffs are entitled to the damages and relief

requested in paragraph 7 of Plaintiff s Complaint.

1(b) Causes Of Action and/or Parties Not Alleged in the Master Complaint: ADDITIONAL DEFENDANTS 1. Pfizer admits that it is a Delaware corporation with its principal place

of business in New York, New York. Further answering, Defendants admit that Pfizer merged with Pharmacia in April 2003. Pfizer admits that, during certain periods of time, it marketed and co-promoted Celebrex® and Bextra®. By way of further answer, Defendants state that paragraph 1 contains legal conclusions to which no answer is required. Defendants deny the remaining allegations contained in paragraph 1 of Plaintiffs Complaint. 2. Paragraph 2 of Plaintiffs Complaint states Plaintiffs own assertions

and legal conclusions to which no response is required. To the extent a response is deemed required, Defendants deny the allegations contained in paragraph 2 of Plaintiffs Complaint.
3.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 4 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

3.

Pharmacia admits that it is a Delaware corporation with its principal

place of business in New Jersey. Defendants admit that in 1933 an entity known as Monsanto Company ( 1933 Monsanto ) was incorporated under the laws of Delaware. Defendants further admit that on March 31, 2000, a subsidiary of the 1933 Monsanto Company merged with Pharmacia & Upjohn, Inc. and the 1933 Monsanto Company changed its name to Pharmacia Corporation. Pharmacia admits that, during certain periods of time, it marketed Celebrex® and Bextra®. By way of further answer, Defendants state that paragraph 3 contains legal conclusions to which no answer is required. Defendants deny the remaining allegations contained in paragraph 3 of Plaintiffs Complaint. 4. Searle admits that it is a wholly-owned subsidiary of Pharmacia

Corporation, which is in turn a wholly-owned subsidiary of Pfizer. Searle is a Delaware limited liability corporation with its principal place of business in Illinois. Searle admits that during certain periods of time it tested, co-promoted and developed Celebrex® and Bextra®. During certain periods of time, Celebrex® and Bextra® were manufactured and packaged for Searle. By way of further answer, Defendants state that paragraph 4 contains legal conclusions to which no answer is required. Defendants deny the remaining allegations contained in paragraph 4 of Plaintiffs Complaint. 5. Defendants incorporate herein their responses to paragraphs 1, 3 and 4

of Plaintiffs Complaint. Defendants deny the remaining allegations contained in paragraph 5 of Plaintiffs Complaint. 6. Paragraph 6 of Plaintiffs Complaint states Plaintiffs own assertions

and legal conclusions to which no response is required. To the extent a response is deemed required, Defendants deny the allegations contained in paragraph 6 of Plaintiff s Complaint. 7. Paragraph 7 of Plaintiffs Complaint states Plaintiffs own assertions
4.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

and legal conclusions to which no response is required. To the extent a response is

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 5 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

deemed required, Defendants deny the allegations contained in paragraph 7 of Plaintiffs Complaint. 8. Paragraph 8 of Plaintiffs Complaint states Plaintiffs own assertions

and legal conclusions to which no response is required. To the extent a response is deemed required, Defendants deny the allegations contained in paragraph 8 of Plaintiffs Complaint. 9. Paragraph 9 of Plaintiffs Complaint states Plaintiffs own assertions

and legal conclusions to which no response is required. To the extent a response is deemed required, Defendants deny the allegations contained in paragraph 9 of Plaintiffs Complaint. 10. Defendants state that, at times relevant to this lawsuit, Bextra® and

Celebrex® were safe and effective when used in accordance with its FDAapproved prescribing information. Defendants state that the potential effects of Bextra® and Celebrex® were adequately described in their FDA-approved prescribing information, which were at all times adequate and comported with applicable standards of care and law. Defendants deny the remaining allegations contained in paragraph 10 of Plaintiffs Complaint. 11. Paragraph 11 of Plaintiffs Complaint states Plaintiffs own assertions

and legal conclusions to which no response is required. To the extent a response is deemed required, Defendants deny the allegations contained in paragraph 11 of Plaintiffs Complaint. GENERAL ALLEGATIONS APPLICABLE TO ALL CAUSES OF ACTION 12. Defendants state that the potential effects of Bextra® and Celebrex®

were adequately described in their FDA-approved prescribing information, which were at all times adequate and comported with applicable standards of care and law. Defendants deny the remaining allegations contained in paragraph 12 of Plaintiffs Complaint.
5.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 6 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

13.

Defendants admit that Bextra® and Celebrex® are selective Cox-2

inhibitor non-steroidal anti-inflammatory drugs ( NSAID ). Defendants admit that Celebrex® received FDA approval on December 31, 1998. Defendants further admit that Celebrex® is indicated for relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis. Defendants state that the potential effects of Celebrex® were adequately described in its FDA-approved prescribing information, which was at all times adequate and comported with applicable standards of care and law. Defendants deny the remaining allegations contained in paragraph 13 of Plaintiffs Complaint. 14. Defendants admit that Bextra® was approved by the FDA on

November 16, 2001. Defendants admit, as indicated in the package insert approved by the FDA, that Bextra® is indicated for use in the relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis, as well as for the treatment of primary dysmenorrhea. Defendants state that the potential effects of Bextra® were adequately described in its FDA-approved prescribing information, which was at all times adequate and comported with applicable standards of care and law. Defendants deny the remaining allegations contained in paragraph 14 of Plaintiffs Complaint. 15. Defendants deny the allegations contained in paragraph 15 of

Plaintiffs Complaint. 16. Defendants deny the allegations contained in paragraph 16 of

Plaintiffs Complaint. 17. Plaintiffs fail to provide the proper context for the allegations

contained in paragraph 17 of Plaintiffs Complaint and therefore, Defendants are without knowledge or information to form a belief as to the truth of the allegations contained in paragraph 17 of Plaintiffs Complaint, and therefore deny the same. 18. Plaintiffs fail to provide the proper context for the allegations
6.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

contained in paragraph 18 of Plaintiffs Complaint and therefore, Defendants are

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 7 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

without knowledge or information to form a belief as to the truth of the allegations contained in paragraph 18 of Plaintiffs Complaint, and therefore deny the same. 19. Plaintiffs fail to provide the proper context for the allegations

contained in paragraph 19 of Plaintiffs Complaint and therefore, Defendants are without knowledge or information to form a belief as to the truth of the allegations contained in paragraph 19 of Plaintiffs Complaint, and therefore deny the same. 20. Plaintiffs fail to provide the proper context for the allegations

contained in paragraph 20 of Plaintiffs Complaint and therefore, Defendants are without knowledge or information to form a belief as to the truth of the allegations contained in paragraph 20 of Plaintiffs Complaint, and therefore deny the same. 21. Plaintiffs fail to provide the proper context for the allegations

contained in paragraph 21 of Plaintiffs Complaint and therefore, Defendants are without knowledge or information to form a belief as to the truth of the allegations contained in paragraph 21 of Plaintiffs Complaint, and therefore deny the same. 22. Plaintiffs fail to provide the proper context for the allegations

contained in paragraph 22 of Plaintiffs Complaint. Defendants state that the potential effects of Bextra® were adequately described in its FDA-approved prescribing information, which was at all times adequate and comported with applicable standards of care and law. Defendants deny the remaining allegations contained in paragraph 22 of Plaintiffs Complaint. 23. Defendants state that the potential effects of Bextra® and Celebrex®

were adequately described in their FDA-approved prescribing information, which were at all times adequate and comported with applicable standards of care and law. Defendants deny the remaining allegations contained in paragraph 23 of Plaintiffs Complaint. 24. Plaintiffs fail to provide the proper context for the allegations

contained in paragraph 24 of Plaintiffs Complaint. Defendants admit that the sale of Bextra® was voluntarily suspended in the U.S. market as of April 7, 2005, at the
7.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 8 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

request of the FDA. Defendants deny the remaining allegations contained in paragraph 24 of Plaintiffs Complaint.

AFFIRMATIVE DEFENSES FIRST AFFIRMATIVE DEFENSE 1. Plaintiffs Complaint fails to state facts sufficient to constitute a cause

of action against these Defendants.

SECOND AFFIRMATIVE DEFENSE 2. This Court lacks personal jurisdiction over these Defendants.

THIRD AFFIRMATIVE DEFENSE 3. Plaintiffs are barred from any recovery against these Defendants by

the doctrines of waiver and estoppel.

FOURTH AFFIRMATIVE DEFENSE 4. The Complaint is barred by reason of the doctrine of laches and by the

fundamental unfairness and prejudice of the excessive and lengthy delay from the date of the alleged use of Bextra® and Celebrex® to the filing of the Complaint.

FIFTH AFFIRMATIVE DEFENSE 5. Defendants state on information and belief that the Complaint and

each purported cause of action contained therein is barred by the applicable statutes of limitation.

SIXTH AFFIRMATIVE DEFENSE 6. Any and all injuries suffered by Plaintiffs, the fact of which is
8.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

expressly denied by these Defendants, were the direct and proximate result of

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 9 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

sensitivities, medical conditions, reactions and/or idiosyncrasies peculiar to Plaintiff that were unknown, unknowable or not reasonably foreseeable to these Defendants, and not, as alleged, as a direct and proximate result of wrongful conduct on the part of these Defendants, the fact of which is expressly denied by these Defendants.

SEVENTH AFFIRMATIVE DEFENSE 7. No act or omission of these Defendants was a substantial factor in

bringing about the alleged injuries of Plaintiffs, nor was any such act or omission a contributing cause thereof, and any alleged acts or omissions of these Defendants were superseded by the acts or omissions of others, including Plaintiffs, which were the independent, intervening and proximate cause of any injury, damage, or loss sustained by Plaintiffs.

EIGHTH AFFIRMATIVE DEFENSE 8. Defendants state on information and belief that any injuries, losses or

damages suffered by Plaintiffs were proximately caused, in whole or in part, by the failure of Plaintiffs to exercise ordinary care and to follow the advice, information, warnings and/or instructions provided with the product and therefore, Plaintiffs recovery, if any, must be diminished by the proportion of the negligence of Plaintiffs which proximately caused or contributed to the alleged injuries, losses or damages.

NINTH AFFIRMATIVE DEFENSE 9. Defendants state on information and belief that any injuries, losses or

damages suffered by the Plaintiffs were proximately caused, in whole or in part, by the negligence or other actionable conduct of persons or entities other than these Defendants.
9.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 10 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

TENTH AFFIRMATIVE DEFENSE 10. Defendants state on information and belief that Plaintiffs failed to

mitigate Plaintiffs injuries, losses or damages, if any, suffered as a result of the incident and facts set forth in the Complaint.

ELEVENTH AFFIRMATIVE DEFENSE 11. Plaintiffs alleged injuries and damages, if any, were the result of the

misuse of Bextra® and Celebrex®. Defendants further allege that if Plaintiff suffered injuries attributable to the use of Bextra® and Celebrex®, which allegations are expressly denied, the injuries, if any, were solely caused and attributable to the unreasonable, unforeseeable and improper use of said pharmaceutical product by Plaintiff and/or third parties.

TWELFTH AFFIRMATIVE DEFENSE 12. Plaintiffs have failed to join all indispensable parties; as a result of

such failure to join, complete relief cannot be accorded to those already parties to the action and will result in prejudice to these Defendants in any possible future litigation.

THIRTEENTH AFFIRMATIVE DEFENSE 13. The manufacture, distribution and sale of Bextra® and Celebrex®

referred to in Plaintiffs Complaint were at all times in compliance with all federal regulations and statutes, and Plaintiffs causes of action are preempted.

FOURTEENTH AFFIRMATIVE DEFENSE 14. To the extent that Plaintiffs assert claims based on these Defendants

alleged adherence or lack of adherence to and compliance with applicable federal
10.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 11 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

laws, regulations, and rules, such claims are preempted by federal law under the Supremacy Clause of the United States Constitution.

FIFTEENTH AFFIRMATIVE DEFENSE 15. Plaintiffs are barred from recovering against Defendants because

Plaintiffs claims are preempted in accordance with the Supremacy Clause of the United States Constitution and by the Federal Food, Drug and Cosmetics Act ( FDCA ), 21 U.S.C. § 301 et. seq., and regulations promulgated thereunder, with the regulations promulgated by the FDA to implement the FDCA, with the purposes and objectives of the FDCA and the FDA s implementing regulations, and with the specific determinations by the FDA specifying the language that should be used in the labeling accompanying the subject pharmaceutical products.

SIXTEENTH AFFIRMATIVE DEFENSE 16. Plaintiffs claims are barred in whole or in part under the applicable

state law because Bextra® and Celebrex® are subject to and received pre-market approval by the FDA under 52 Stat. 1040; 21 U.S.C. § 301.

SEVENTEENTH AFFIRMATIVE DEFENSE 17. Plaintiffs claims are barred in whole or in part by the deference given

to the primary jurisdiction of the FDA over Bextra® and Celebrex® under applicable federal laws, regulations, and rules.

EIGHTEENTH AFFIRMATIVE DEFENSE 18. Plaintiffs claims are barred in whole or in part because there is no

private right of action concerning matters regulated by the FDA under applicable federal laws, regulations, and rules.
11.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 12 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

NINETEENTH AFFIRMATIVE DEFENSE 19. The warning, labeling, advertising and sale of Bextra® and

Celebrex® complied at all times with the FDCA, 21 U.S.C. § 300 et seq. and the Federal Trade Commission Act, 15 U.S.C. § 41 et seq. Consequently, Plaintiffs Complaint is preempted by these acts and compliance with these acts constitutes a complete or partial defense to the allegations of Plaintiffs Complaint against Defendants, including any claim for punitive damages. Alternatively, Defendants are entitled to a presumption that Bextra® and Celebrex® are not defective or unreasonably dangerous and that their labeling was adequate.

TWENTIETH AFFIRMATIVE DEFENSE 20. If Bextra® and Celebrex® manufactured or sold by these Defendants

were involved in the incident alleged in the Complaint herein, which these Defendants deny, then and in that event, Bextra® and Celebrex® were not defective at the time that they left the control of these Defendants.

TWENTY-FIRST AFFIRMATIVE DEFENSE 21. Applicable definitions of manufacturing defect and design defect, and

standards for determining whether there has been an actionable failure to warn, are unconstitutional in that, among other things, they are void for vagueness and an undue burden on interstate commerce, as well as an impermissible effort to regulate in an area that previously has been preempted by the federal government.

TWENTY-SECOND AFFIRMATIVE DEFENSE 22. Bextra® and Celebrex® conformed to the then current state of the art.

Further, the then current state of medical, scientific and industrial knowledge, art and practice was such that these Defendants did not know, and could not
12.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 13 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

reasonably have known, that Bextra® and Celebrex® might pose a risk of harm in normal and foreseeable use.

TWENTY-THIRD AFFIRMATIVE DEFENSE 23. Defendants allege that Bextra® and Celebrex® were fit and proper for

their intended purpose and that the utility of Bextra® and Celebrex® outweigh any possible risk inherent in the use of Bextra® and Celebrex®.

TWENTY-FOURTH AFFIRMATIVE DEFENSE 24. Defendants are informed and believe and thereon allege that, at or

about the times, dates and places mentioned in the Complaint, if any risk was attendant upon Plaintiffs, which Defendants deny, Plaintiffs knew full well of such risk, were warned of such risk and voluntarily, and without compulsion or coercion, encountered and assumed such risk.

TWENTY-FIFTH AFFIRMATIVE DEFENSE 25. Bextra® and Celebrex® have at all relevant times been available only

upon the prescription of a licensed physician, and Plaintiffs prescribing physicians stood in the position of the learned intermediaries between Defendants and Plaintiffs. To the extent that Plaintiffs assert claims based on an alleged failure by Defendants to warn Plaintiffs directly of alleged dangers associated with Bextra® and Celebrex®, such claims are barred because Defendants have discharged their duty to warn in their warnings to the prescribing physicians, under the learned intermediary doctrine.

TWENTY-SIXTH AFFIRMATIVE DEFENSE 26. Plaintiffs claims against Defendants are barred under § 6(c) of the
13.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Restatement of Torts (Third): Products Liability.

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 14 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

TWENTY-SEVENTH AFFIRMATIVE DEFENSE 27. Plaintiffs strict liability claims are barred by the unavoidably

dangerous product defense stated in Comment k to § 402A of the Restatement (Second) of Torts.

TWENTY-EIGHTH AFFIRMATIVE DEFENSE 28. Plaintiffs claims are barred in whole or in part because Defendants

provided adequate "direction or warnings" as to the use of Bextra® and Celebrex® within the meaning of Comment j to § 402A of the Restatement (Second) of Torts.

TWENTY-NINTH AFFIRMATIVE DEFENSE 29. Plaintiffs claims are barred in whole or in part because Bextra® and

Celebrex® "provide[d] net benefits for a class of patients" within the meaning of Comment f to § 6 of the Restatement (Third) of Torts: Products Liability.

THIRTIETH AFFIRMATIVE DEFENSE 30. Plaintiffs claims are barred under § 4, et seq., of the Restatement

(Third) of Torts: Products Liability.

THIRTY-FIRST AFFIRMATIVE DEFENSE 31. Defendants allege that in the event that reliance was placed upon

Defendants nonconformance to an express representation, this action is barred since there was no reliance upon representations, if any, of these Defendants.

THIRTY-SECOND AFFIRMATIVE DEFENSE 32. Plaintiffs claims of fraud and concealment are barred by reason of

Plaintiffs failure to allege the circumstances constituting the alleged fraud and concealment with particularity.
14.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 15 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

THIRTY-THIRD AFFIRMATIVE DEFENSE 33. Defendants are informed and believe and thereon allege that Plaintiffs

failed to provide Defendants with timely notice of any alleged nonconformance with any express representation.

THIRTY-FOURTH AFFIRMATIVE DEFENSE 34. To the extent that Plaintiffs seek punitive damages for the conduct

which allegedly caused injuries asserted in the Complaint, punitive damages are barred or reduced by applicable law or statute or, in the alternative, are unconstitutional insofar as they violate the due process protections afforded by the United States Constitution, the excessive fines clause of the Eighth Amendment of the United States Constitution, the Commerce Clause of the United States Constitution, the Full Faith and Credit Clause of the United States Constitution, and applicable state provisions. Any law, statute, or other authority purporting to permit the recovery of punitive damages in this case is unconstitutional, facially and as applied, to the extent that, without limitation, it: (1) lacks constitutionally sufficient standards to guide and restrain the jury's discretion in determining whether to award punitive damages and/or the amount, if any; (2) is void for vagueness in that it failed to provide adequate advance notice as to what conduct will result in punitive damages; (3) permits recovery of punitive-damages based on out-of state conduct, conduct that complied with applicable law, or conduct that was not directed, or did not proximately cause harm, to Plaintiffs; (4) permits recovery of punitive damages in an amount that is not both reasonable and proportionate to the amount of harm, if any, to Plaintiffs and to the amount of compensatory damages; if any; (5) permits jury consideration of net worth or other financial information relating to these Defendants; (6) lacks constitutionally sufficient standards to be applied by the trial court in post-verdict review of any
15.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 16 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

punitive damages awards; (7) lacks constitutionally sufficient standards for appellate review of punitive damages awards; and (8) otherwise fails to satisfy Supreme Court precedent.

THIRTY-FIFTH AFFIRMATIVE DEFENSE 35. To the extent that Plaintiffs seek punitive damages for an alleged act

or omission of these Defendants, no act or omission was oppressive, fraudulent, or malicious, and therefore, any award of punitive damages is barred.

THIRTY-SIXTH AFFIRMATIVE DEFENSE 36. Plaintiffs claims are barred in whole or in part because all acts or

omissions by these Defendants (or their agents or representatives) were privileged or justified and any claim based thereon is barred.

THIRTY-SEVENTH AFFIRMATIVE DEFENSE 37. Plaintiffs claims are barred in whole or in part because Plaintiffs lack

standing to bring such claims.

THIRTY-EIGHTH AFFIRMATIVE DEFENSE 38. Plaintiffs claims are barred in whole or in part because Defendants

have been improperly joined in this action.

THIRTY-NINTH AFFIRMATIVE DEFENSE 39. Plaintiffs were contributorily or comparatively negligent, which

contributory or comparative negligence constitutes a proximate cause of harm to Plaintiffs.

16.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 17 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

FORTIETH AFFIRMATIVE DEFENSE 40. Plaintiffs claims are barred because the Plaintiff would have taken

Bextra® and Celebrex® even if Bextra® and Celebrex® labeling contained the information that Plaintiffs contend should have been provided.

FORTY-FIRST AFFIRMATIVE DEFENSE 41. Plaintiffs claims are barred, in whole or in part, because the

advertisements, if any, and labeling with respect to Bextra® and Celebrex® were not false or misleading and, therefore, constitute protected commercial speech under the applicable provisions of the United States Constitution.

FORTY-SECOND AFFIRMATIVE DEFENSE 42. To the extent that Plaintiffs claims are based on a theory providing

for liability without proof of causation, the claims violate Defendants rights under the United States Constitution.

FORTY-THIRD AFFIRMATIVE DEFENSE 43. To the extent Plaintiffs are seeking recovery for benefits entitled to be

received or actually received from any other source for injuries alleged in the Complaint, such benefits are not recoverable in this action.

FORTY-FOURTH AFFIRMATIVE DEFENSE 44. Defendants made no warranties of any kind, express or implied, or

any representations of any nature whatsoever to Plaintiffs herein. Additionally, as a manufacturer and not a seller, Defendants are not subject to liability for implied warranties without privity, i.e., proof of direct and specific transactions between the Plaintiffs and Defendants. If any such warranties were made, whether express or implied, which Defendants specifically deny, then Plaintiffs failed to give timely
17.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 18 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

notice of any breach thereof.

FORTY-FIFTH AFFIRMATIVE DEFENSE 45. Plaintiffs claims are barred, in whole or in part, by the doctrine of

accord and satisfaction.

FORTY-SIXTH AFFIRMATIVE DEFENSE 46. Defendants are entitled to credit for any settlement of claims for

alleged injuries and damages made by Plaintiffs with any other defendant or other person or entity.

FORTY-SEVENTH AFFIRMATIVE DEFENSE 47. Plaintiffs claims are barred in whole or part because they have been

filed in an improper venue.

FORTY-EIGHTH AFFIRMATIVE DEFENSE 48. To the extent Plaintiffs seek restitution or damages on behalf of

individuals who used Bextra® and Celebrex® and suffered no damage or loss as a result thereof, restitution or damages are unavailable as nothing has been taken from those individuals, who allegedly could have an equitable basis for restitution or damages.

FORTY-NINTH AFFIRMATIVE DEFENSE 49. Plaintiffs claims for restitution for products previously used are barred in

whole or in part because the Plaintiffs received benefits from the subject pharmaceutical products and nothing was wrongfully taken from such Plaintiffs.

18.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 19 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

FIFTIETH AFFIRMATIVE DEFENSE 50. Defendants intend to rely upon such other affirmative defenses as may

become available or apparent during the course of investigation, discovery, or trial, and reserves the right to amend the Answer to assert such other defenses to which it may be entitled.

PRAYER WHEREFORE, Defendants pray for judgment as follows: 1. Complaint; 2. 3. 4. That the Complaint be dismissed; That Defendants be awarded its costs for this lawsuit; That the trier of fact determine what percentage of the combined fault That Plaintiffs take nothing from Defendants by reason of the

or other liability of all persons whose fault or other liability proximately caused Plaintiffs alleged injuries, losses or damages is attributable to each person; 5. That any judgment for damages against Defendants in favor of

Plaintiffs be no greater than an amount which equals its proportionate share, if any, of the total fault or other liability which proximately caused Plaintiffs injuries and damages; and 6. appropriate. DATED: December 21, 2006 TUCKER ELLIS & WEST LLP That Defendants have such other and further relief as the Court deems

By: /S/ Tae-Yoon Kim Tae-Yoon Kim Attorneys for Defendants PFIZER INC., PHARMACIA CORPORATION, and G.D. SEARLE LLC
19.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 20 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

JURY DEMAND Defendants Pfizer Inc., Pharmacia Corporation, and G.D. Searle LLC hereby demand a trial by jury of all the facts and issues in this case pursuant to 38(b) of the Federal Rules of Civil Procedure. DATED: December 21, 2006 TUCKER ELLIS & WEST LLP

By: /S/ Tae-Yoon Kim Tae-Yoon Kim Attorneys for Defendants PFIZER INC., PHARMACIA CORPORATION, and G.D. SEARLE LLC

20.
DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 21 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

PROOF OF SERVICE STATE OF CALIFORNIA, COUNTY OF LOS ANGELES I declare that I am a citizen of the United States and a resident of Los Angeles, California or employed in the County of Los Angeles, State of California. I am over the age of eighteen (18) and not a party to the within action. My business address is Tucker Ellis & West LLP, 1000 Wilshire Blvd., Suite 1800, Los Angeles, California 90017-2475. On December 21, 2006, I served the foregoing document DEFENDANTS PFIZER INC., PHARMACIA CORPORATION AND G.D. SEARLE LLC S ANSWER TO COMPLAINT by placing a true and correct copy of each document thereof, enclosed in a sealed envelope(s), addressed as follows: PLEASE SEE ATTACHED SERVICE LIST (X) ( ) I caused such envelope(s) with postage thereon fully prepaid to be placed in the United States mail at Los Angeles, California. By Certified mail service return receipt requested, I caused such envelope(s) with postage thereon fully prepaid to be placed in the United States mail at Los Angeles, California. By Personal Service, I caused such envelope(s) to be delivered by hand to the individuals so indicated at the address listed. By overnight courier, I caused the above-referenced document(s) to be delivered to an overnight courier service for delivery to the above address(es) or on the attached service list. By facsimile machine, I caused the above-referenced document(s) to be transmitted to the person(s) named above or on the attached service list at the facsimile numbers given thereat. I declare that I am employed in the office of the Bar of this Court at whose direction the service was made. I declare under penalty of perjury under the laws of the State of California that the above is true and correct. Executed on December 21, 2006 at Los Angeles, California.

( ) ( )

( )

(X) (X)

/S/ Maria Valdez Maria Valdez

TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

PROOF OF SERVICE
LAimanage / 28762 / 00002 / 583193 / 1 /

Case 3:07-cv-03448-CRB

Document 1-14

Filed 07/02/2007

Page 22 of 22

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TUCKER ELLIS & WEST LLP
1000 Wilshire Boulevard Suite 1800 Los Angeles, CA 90017-2475

SERVICE LIST Theodore J. Holt, Esq. David R. Zarka, Esq. Alissa S. Holt, Esq. HACKARD & HOLT 11335 Gold Express Drive, Suite 105 Gold River, CA 95670 Tel: 916.853.3000 Fax: 916.853.3010 COUNSEL FOR PLAINTIFFS

2.
PROOF OF SERVICE
LAimanage / 28762 / 00002 / 583193 / 1 /